Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Tandem Diabetes Care, Inc. (NASDAQ:TNDM), that sends out a positive message to the company's shareholders.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
The Last 12 Months Of Insider Transactions At Tandem Diabetes Care
Over the last year, we can see that the biggest insider purchase was by Independent Director Dick Allen for US$295k worth of shares, at about US$29.47 per share. That implies that an insider found the current price of US$31.86 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider purchases were made at close to current prices.
In the last twelve months Tandem Diabetes Care insiders were buying shares, but not selling. They paid about US$24.06 on average. To my mind it is good that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
NasdaqGM:TNDM Insider Trading Volume April 16th 2024
Tandem Diabetes Care is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Tandem Diabetes Care insiders own about US$15m worth of shares. That equates to 0.7% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Do The Tandem Diabetes Care Insider Transactions Indicate?
There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Tandem Diabetes Care and we see no evidence to suggest they are worried about the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example - Tandem Diabetes Care has 2 warning signs we think you should be aware of.
But note: Tandem Diabetes Care may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
通常情況下,一個內部人購買股票,可能並不是一件大事。但是,當多位內部人士像Tandem Diabetes Care, Inc.(納斯達克股票代碼:TNDM)一樣買入時,這向該公司的股東發出了一個積極的信息。
儘管內幕交易並不是長期投資中最重要的事情,但邏輯表明,你應該注意內部人士是在買入還是賣出股票。
Tandem Diabetes Care最近12個月的內部交易
在過去的一年中,我們可以看到,最大的內部收購是獨立董事迪克·艾倫購買了價值29.5萬美元的股票,每股價格約爲29.47美元。這意味着一位內部人士發現目前每股31.86美元的價格很有吸引力。當然,他們可能改變了主意。但這表明他們很樂觀。如果有人以遠低於當前價格的價格購買股票,這是平衡的好兆頭,但請記住,他們可能再也看不到價值。在這種情況下,我們很高興地報告,內幕收購是以接近當前的價格進行的。
在過去的十二個月中,Tandem Diabetes Care內部人士一直在買入股票,但沒有賣出。他們平均支付約24.06美元。在我看來,內部人士將自己的錢投資於公司是件好事。但是,我們確實注意到,他們的買入價格遠低於今天的股價。您可以看到下圖所示的去年的內部交易(公司和個人)。通過點擊下面的圖表,你可以看到每筆內部交易的確切細節!
納斯達克通用汽車公司:TNDM 內部交易量 2024 年 4 月 16 日
Tandem Diabetes Care並不是內部人士唯一買入的股票。對於那些喜歡尋找獲利投資的人來說,這份最近有內幕收購的成長型公司的免費清單可能就是入場券。
內部所有權
測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。我們通常希望看到相當高的內部所有權水平。Tandem糖尿病護理內部人士擁有價值約1500萬美元的股票。這相當於該公司的0.7%。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。
那麼,Tandem Diabetes Care的內部交易表明了什麼?
在過去的三個月中,沒有任何內部交易——這並不意味着什麼。但是,在過去的一年中,內部人士對該股表現出了更大的興趣。業內人士擁有Tandem Diabetes Care的股份,我們沒有發現任何證據表明他們對未來感到擔憂。因此,這些內部交易可以幫助我們建立有關股票的論點,但也值得了解這家公司面臨的風險。例如,Tandem Diabetes Care 有 2 個警告信號,我們認爲您應該注意。
但請注意:Tandem Diabetes Care可能不是最好的買入股票。因此,來看看這份投資回報率高、負債率低的有趣公司的免費清單。
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。